The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer by Lisztwan, Joanna et al.
Open Access
Available online http://breast-cancer-research.com/content/10/4/R56
Page 1 of 13
(page number not for citation purposes)
Vol 10 No 4 Research article
The aromatase inhibitor letrozole and inhibitors of insulin-like 
growth factor I receptor synergistically induce apoptosis in in vitro 
models of estrogen-dependent breast cancer
Joanna Lisztwan1, Astrid Pornon1, Bin Chen2, Shiuan Chen2 and Dean B Evans1
1Novartis Institutes of BioMedical Research Basel, Oncology Research, Klybeckstrasse 141, CH-4057, Basel, Switzerland
2Department of Surgical Research, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA
Corresponding author: Joanna Lisztwan, joanna.lisztwan@novartis.com
Revisions received: 25 Apr 2008 Revisions requested: 10 Jun 2008 Revisions received: 17 Jun 2008 Accepted: 8 Jul 2008 Published: 8 Jul 2008
Breast Cancer Research 2008, 10:R56 (doi:10.1186/bcr2113)
This article is online at: http://breast-cancer-research.com/content/10/4/R56
© 2008 Lisztwan et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Endocrine-dependent, estrogen receptor positive
breast cancer cells proliferate in response to estrogens,
synthesized by the cytochrome p450 aromatase enzyme.
Letrozole is a potent nonsteroidal aromatase inhibitor that is
registered for the treatment of postmenopausal women with
advanced metastatic breast cancers and in the neoadjuvant,
early, and extended adjuvant indications. Because crosstalk
exists between estrogen receptor and insulin-like growth factor
I receptor (IGF-IR), the effect of combining a selective IGF-IR
inhibitor (NVP-AEW541) with letrozole was assessed in two
independent  in vitro models of estrogen-dependent breast
cancer.
Methods MCF7 and T47D cells stably expressing aromatase
(MCF7/Aro and T47D/Aro) were used as in vitro models of
aromatase-driven breast cancer. The role of the IGF-IR pathway
in breast cancer cells stimulated only by 17β-estradiol or
androstenedione was assessed by proliferation assays. The
combination of letrozole and NVP-AEW541 was assessed for
synergy in inhibiting cell proliferation using Chou-Talalay derived
equations. Finally, combination or single agent effects on
proliferation and apoptosis were assessed using proliferation
assays, flow cytometry, and immunoblotting.
Results Both MCF7 and T47D cells, as well as MCF7/Aro and
T47D/Aro, exhibited sensitivity to inhibition of 17β-estradiol
dependent proliferation by NVP-AEW541. Letrozole combined
with NVP-AEW541 synergistically inhibited androstenedione-
dependent proliferation in aromatase-expressing cells with
combination index values of 0.6 or less. Synergistic combination
effects correlated with higher levels of apoptosis as compared
with cells treated with the single agent alone. Treatment with
either agent also appeared to inhibit IGF-IR signalling via
phosphoinositide 3-kinase. Notably, IGF-IR inhibition had limited
effect on estrogen-dependent proliferation in the cell lines, but
was clearly required for survival, suggesting that the
combination of letrozole and IGF-IR inhibition sensitizes cells to
apoptosis.
Conclusion Inhibition of the IGF-IR pathway and aromatase was
synergistic in two independent estrogen-dependent in vitro
models of breast cancer. Moreover, synergism of NVP-AEW541
and letrozole correlated with induction of apoptosis, but not cell
cycle arrest, in the cell lines tested. Combination of IGF-IR
inhibitors and letrozole may hold promise for the treatment of
patients with estrogen-dependent breast cancers.
Introduction
Breast cancer is the leading cause of death among women in
industrialized countries. Approximately two-thirds of breast
cancers and breast cancer derived cells exhibit hormone-
dependent growth, primarily involving estrogen. Different hor-
monal therapy approaches that are currently in use or in clini-
cal development for patients with breast cancer prevent either
estrogen synthesis or estrogen binding to nuclear estrogen
receptors (ERs), thereby downregulating ER-mediated cell
proliferation. Letrozole is a potent nonsteroidal aromatase
inhibitor, which is an effective treatment for postmenopausal
women with advanced breast cancer and in the neoadjuvant,
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early, and extended adjuvant indications [1-7]. Letrozole acts
through reversible binding to the aromatase-cytochrome P450
heme component, thereby blocking the conversion of testo-
sterone and androstenedione (Δ4A) into estrone and 17β-
estradiol (E2), respectively. A series of studies have shown the
effectiveness of letrozole in blocking proliferation of aro-
matase-expressing, ER-positive tumor cells and its benefits
over tamoxifen (for review [2]). Nevertheless, patients may
eventually develop resistance through upregulation of growth
factor receptor pathways, indicating that a combination ther-
apy approach would be more beneficial in terms of prolonging
patient response to letrozole [8].
The insulin-like growth factor I receptor (IGF-IR) is a trans-
membrane receptor tyrosine kinase that is activated by its lig-
ands, insulin-like growth factor (IGF)-I and IGF-II, as well as to
some extent insulin [9]. Activation of tyrosine kinase activity
upon ligand binding results in trans-subunit auto-phosphoryla-
tion of the receptor and stimulation of signaling cascades,
including the mitogen-activated protein kinase (MAPK) and
phosphoinositide 3-kinase (PI3K) pathways. IGF-IR signaling
has been reported to promote proliferation, growth, survival,
transformation, metastasis, and angiogenesis. Moreover, high
levels of IGF-IR and/or its activating ligands IGF-I and IGF-II
have been associated with various types of cancers [10,11].
In keeping with these observations, targeted over-expression
of IGF-IR in various tissues (including mammary gland, pancre-
atic islets, and basal epidermis) results in tumor development
and, in some cases, formation of metastases in mice [12-15].
Conversely, inhibition of tumor growth in different mouse mod-
els was observed using antibodies that are capable of block-
ing IGF-IR auto-phosphorylation and signaling, or selective
small-molecular-weight inhibitors against the receptor [16,17].
NVP-AEW541 (referred to subsequently in this report as
AEW541) was characterized as an orally bioavailable, selec-
tive IGF-IR inhibitor for the targeted treatment of various tumor
types that are dependent on IGF-IR-mediated signaling for
proliferation/survival [18]. Notably, although AEW541 exhibits
antiproliferative/proapoptotic responses in vitro and antitumor
activity in vivo as a single agent, it is believed that IGF-I sign-
aling inhibition could be most effective in combination with
other therapies [19]. For example, AEW541 enhanced sup-
pression of Ewing's sarcoma xenograft growth when com-
bined with vincristine [20].
Existing evidence indicates that ER and IGF-IR exhibit bidirec-
tional regulation in vitro and in vivo [16,21,22]. In vitro, estro-
gen and IGF-I were shown to act synergistically to induce S-
phase entry of MCF7 breast cancer cells [23,24]. In the
breast, crosstalk between the two pathways plays a key role in
the development of normal mammary gland as well as breast
carcinoma [25]. Moreover, the expressions of ER and IGF-I
family members have prognostic significance [26-32], and
there is a positive correlation between IGF-I concentration and
risk for cancer in premenopausal women [33]. Considering
that a strong link exists between both receptors and their
involvement in breast cancer progression, a combination of ER
and IGF-I pathway inhibitors represents a rational therapeutic
strategy. We determined to begin examining this issue using
in vitro models of estrogen-dependent breast cancer.
Materials and methods
Cell culture
MCF7/Aro, MCF7 3(1), T47D/Aro and T47D, human breast
carcinoma cells stably transfected with the aromatase or
empty control expression vectors, respectively, carrying the
neomycin (G418) resistance gene, were generated and char-
acterized by Sun and coworkers [34]. MCF-7/Aro is a very sta-
ble cell line and aromatase expression remains in the absence
of G418, whereas T47D/Aro requires G418 during culture. All
cell lines are dependent on E2 for cell proliferation. Cells were
therefore maintained in minimum essential medium with
Earle's balanced salts (MEM-EBS) supplemented with 10%
fetal calf serum (FCS), 2 mmol/l L-glutamine, 1 mmol/l sodium
pyruvate, nonessential amino acids, penicillin/streptomycin,
and 0.5 mg/ml G418 (BioConcept, Basel, Switzerland). Estro-
gen-induced cell proliferation assays were performed with
steroid-depleted medium, in which MEM-EBS and FCS were
replaced with MEM-EBS without phenol red and charcoal-
stripped FCS (Hyclone, Logan, UT, USA). Proliferation was
induced with Δ4A or E2 (Sigma-Aldrich, St Louis, MO, USA),
which were dissolved in ethanol as stock solutions of 10
mmol/l and 1 mmol/l, respectively. NVP-AEW541 and letro-
zole were synthesized in the laboratories of Novartis Institutes
for Biomedical Research (Basel, Switzerland) and were dis-
solved in dimethyl sulfoxide (DMSO; 10 mmol/l) and ethanol
(1 mmol/l) as stock solutions.
In vitro proliferation assay
MCF7 3(1) and MCF7/Aro cells at a confluency of 30% to
40% were steroid-deprived for 3 days, trypsinized with trypsin
lacking phenol red (Sigma-Aldrich), and seeded in six-well
plates (105 MCF7/Aro cells per well and 1.2 × 105 MCF7 3(1)
cells per well). Two days later, steroid-deprived media contain-
ing 1 nmol/l E2 or 10 nmol/l Δ4A was added to the cells to
induce proliferation. Vehicle control or compound was added
simultaneously and left for 6 days on the cells. Media, E2, or
Δ4A, and compound were renewed every 48 hours. Each con-
dition was tested in triplicate. After treatment, cells were fixed
by addition of 20% glutaraldehyde, stained by addition of
0.05% methylene blue, washed with water to remove excess
methylene blue, and 3% HCl was added to each well to dis-
solve the methylene blue stain. The absorbance was read at
650 nmol/l, and percentage inhibition was calculated using
Softmaxpro software (Molecular Devices Corp., Sunnyvale,
CA, USA). More specifically, cells treated with either E2 or Δ4A
in the presence of DMSO were considered to represent
100% proliferation, and subsequently compound-treated cells
were compared with these standards.Available online http://breast-cancer-research.com/content/10/4/R56
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T47D and T47D/Aro cells were similarly steroid-deprived for 3
days and then seeded in 96-well plates (6,000 cells per well).
Steroid-deprived cells were treated with hormone and com-
pound every other day for 6 days, as described above. Each
condition was tested in triplicate. Proliferation assay was car-
ried out using a CellTiter 96® AQueous One Solution Cell Pro-
liferation Assay (Promega, Madison, WI, USA), and
percentage inhibition was calculated as described above.
Statistical analysis
Combination studies were performed at a ratio of 4.85:1
(letrozole:AEW541) in MCF7/Aro cells, and 20:1
(AEW541:letrozole) in T47D/Aro cells. Each condition was
tested in triplicate (single agent and combination) and the
average percentage inhibition of cell growth in response to
specific compound concentrations was entered into the Cal-
cuSyn program for dose-effect analysis (Biosoft, Cambridge,
UK). Median effect and combination index were calculated in
accordance with the Chou-Talalay derived equations [35] and
data are represented as nonexclusive Monte Carlo values.
Combinations were performed at a constant ratio (derived
from the calculated average 50% inhibitory concentration
[IC50] values).
Flow cytometry analysis
To analyze the cell cycle profile, treated MCF7/Aro or T47D/
Aro cells were fixed overnight with 70% EtOH at -20°C and
stained with propidium iodide buffer (38 mmol/l sodium citrate
[pH 7.5], 69 μmol/l propidium iodide, and 120 μg/ml RNase
A). To analyze the numbers of apoptotic cells, treated MCF7/
Aro cells were processed for Annexin V/7-AAD (Becton Dick-
inson, San Diego, CA, USA) staining, inn accordance with the
manufacturer's instructions. Cell cycle distribution and per-
centage of apoptotic cells was analyzed with a Becton Dickin-
son FACSCalibur flow cytometer. More specifically, cells were
gated for DNA staining (FLH-3, 7-AAD) and apoptosis (FLH-
1, Annexin V), whereby apoptotic cells are represented in the
two right-hand quadrants of the FACS image (high FLH-1
staining).
Western blotting
To analyze levels of signaling proteins, the treated MCF7/Aro
cells were processed for Western blotting with the following
antibodies: anti-IGF-IRβ (C-20; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-IRS-1, anti-PKBα (Upstate, Char-
lottesville, VA, USA), anti-phospho-IRS-1 (pY612; Invitrogen,
Carlsbad, CA, USA), anti-ERα (DakoCytomation, Glostrup,
Denmark), anti-phospho-PKB (Ser473), anti-p44/42 MAPK,
anti-phospho-p44/42 MAPK (Thr202Tyr204), anti-human
caspase 9, anti-PARP (Cell Signaling Technology Inc., Bev-
erly, MA, USA), and anti-β-actin (Abcam, Cambridge, UK).
Results
Estrogen-dependent proliferation of MCF7/Aro and 
T47D/Aro cells exhibits sensitivity to IGF-IR inhibition
In order to assess the role played by IGF-IR in E2-induced pro-
liferation, we selected two established ER-positive breast can-
cer cell lines, namely MCF7 and T47D. MCF7 cells are known
to be E2 dependent as well as very sensitive to the growth
inhibitory effects of AEW541 in an IGF-I-dependent survival
assay (IC50 162 ± 16 nmol/l) and a soft agar anchorage-inde-
pendent growth assay (IC50 105 ± 18 nmol/l) [18]. By steroid-
depriving either the parental cells or cells over-expressing aro-
matase (namely MCF7/Aro and T47D/Aro), we determined
whether AEW541 can inhibit their E2-dependent proliferation.
Table 1 summarizes the dose-dependent inhibitory effect of
AEW541 on E2-dependent growth of the cell lines in three
independent experiments. Notably, in IGF-I-dependent prolif-
eration assays the analysis of MCF7 cells revealed an IC 50
value of 150 ± 8 nmol/l, pointing to a key role of IGF-IR in
mediating estrogen-dependent proliferation in MCF7 cells
[22]. T74D cells also exhibited sensitivity to AEW541, albeit
at about fourfold higher concentrations as compared with
MCF7 cells (IC50 values: 150 ± 8 nmol/l versus 544 ± 133
nmol/l).
Table 1
Estrogen-dependent proliferation of breast cancer cell lines is dependent on IGF-IR
Cell line Compound E2 IC50 (nmol/l) Δ4A IC20
a (nmol/l) Δ4A IC50 (nmol/l) Δ4A IC80
a (nmol/l)
MCF7 3(1) AEW541 150 ± 8 NA NA NA
MCF7/Aro AEW541 91 ± 37 66 ± 15 130 ± 16 280 ± 36
Letrozole NA 150 ± 8 444 ± 89 1,160 ± 372
T47D AEW541 544 ± 133 NA NA NA
T47D/Aro AEW541 612 ± 124 733 ± 422 4,474 ± 2,613 31,272 ± 2,300
Letrozole NA 9 ± 7 67 ± 29 2171 ± 502
Steroid-deprived MCF7, MCF7/Aro, T47D, and T47D/Aro cells were treated with either 17β-estradiol (E2) or androstenedione (Δ4A) in the 
presence of increasing concentrations of letrozole or AEW541 for 6 days. Percentage inhibition of proliferation was determined as described in 
the text. The average inhibitory concentrations at 20%, 50%, and 80% (IC20, IC50, and IC80, respectively) ± standard deviation was calculated for 
MCF7 cell lines. aIC25 and IC75 values were calculated for T47D cell lines. IGF-IR, insulin-like growth factor I receptor; NA, not applicable.Breast Cancer Research    Vol 10 No 4    Lisztwan et al.
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Combination of letrozole and IGF-IR inhibition is 
synergistic for inhibition of estrogen-dependent 
proliferation
In order to establish the appropriate experimental conditions in
which to monitor the effects of letrozole as a single agent or in
combination, it was necessary to replace E2 with  Δ4A, an
androgen that is processed by aromatase. By titrating
AEW541 or letrozole onto MCF7/Aro or T47D/Aro cells in the
presence of Δ4A, we observed a dose-dependent inhibition of
cell growth by both AEW541 and letrozole in three independ-
ent experiments (Table 1). Using IC20, IC50, and IC80 values,
we determined an appropriate concentration range for both
letrozole and AEW541 in the combination study. Each experi-
ment required titration of AEW541 and letrozole as single
agents as well as in combination at a fixed ratio. Percentage
inhibition of cell proliferation for single agent concentrations
and combination concentrations were entered into CalcuSyn
and the median effect and combination index calculated
according to the Chou-Talalay derived equations [35] (Figure
1, Table 2, and Additional file 1).
Three independent experiments revealed excellent linear cor-
relation coefficient r values (>0.97) and dose-effect fit curves
(data not shown). Moreover, the combination index curves
(Figure 1a,c) and conservative isobolograms (Figure 1b,d)
indicated synergism of activity between letrozole and
AEW541 in both cell lines. More specifically, the data indicate
that AEW541 and letrozole are synergistic, especially at
higher affected fractions (Fa 0.75 and 0.9), for which combi-
nation index is 0.6 or less (Table 2). Strikingly, dose response
index values for AEW541 were generally higher than for letro-
zole (ranging from 5.2 to 10 for AEW541 versus 1.1 to 6.5 for
letrozole), indicating AEW541 concentrations could be
strongly decreased in the presence of letrozole. In summary,
these data suggest that a combination of IGF-IR and aro-
matase inhibition in estrogen-dependent breast cancer cell
Figure 1
Combination of AEW541 and letrozole is synergistic in inhibiting androstenedione-dependent proliferation Combination of AEW541 and letrozole is synergistic in inhibiting androstenedione-dependent proliferation. Steroid-deprived MCF7/Aro (upper pan-
els) and T47D/Aro (lower panels) cells were treated with androstenedione (Δ4A) in the presence of increasing concentrations of letrozole and/or 
AEW541 for 6 days. Percentage inhibition of proliferation was determined (as described in the text), and combination index (CI) values of the two 
agents plotted, according to a (a,c) nonexclusive Monte Carlo extrapolation. (b,d) Similarly, a conservative isobologram was plotted. ED, effective 
dose; s.d., standard deviation.Available online http://breast-cancer-research.com/content/10/4/R56
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lines is synergistic in terms of inhibitory activity.
Combination of AEW541 and letrozole are not 
synergistic in inducing a cell cycle arrest
In order to understand the mechanisms that underlie the syn-
ergistic antiproliferative actions of AEW541 and letrozole, cell
cycle profiles were analyzed following addition of these
agents. The most reliable concentrations, corresponding to
the above calculated Fa 0.75 (T47D/Aro) or 0.9 (MCF-7/Aro;
Table 2), were chosen to be used alone or in combination.
Note that although concentrations were within an acceptable
range for both agents, namely close to the single agent IC50
values for both AEW541 and letrozole, they were still subopti-
mal for achieving IC90 (or IC75) and therefore allowed detec-
tion of synergistic effects. Table 3 summarizes cell cycle
profile results obtained in one experiment, although data
looked highly comparable over a set of three independent
experiments.
Normal cell cycle progression in our system was clearly
dependent on estrogen, as indicated by an accumulation in G1
phase in the absence of Δ4A (Figure 2 and Table 3; compo-
nents labeled -Δ4A). Moreover, a normal cell cycle distribution
was observed in the presence of Δ4A (Figure 2 and Table 3;
components labeled +Δ4A). When letrozole was added as a
single agent or in combination with AEW541, cell cycle pro-
files resembled that of cells grown in the absence of Δ4A
(Table 3). More specifically, MCF7/Aro cells were 78% in G1
without Δ4A, 40% with Δ4A, and 74% and 78% in the pres-
ence of Δ4A and letrozole (similar for T47D/Aro, with values of
87%, 78%, 84%, and 87% in G1 phase, respectively). While
AEW541 alone exhibited almost no effects on the cell cycle
profile in MCF7/Aro cells (compare 40% G1 versus 44%),
T47D/Aro cells accumulated in G1 phase to almost as high lev-
els as without Δ4A (compare 78% G1 versus 84%). This
would suggest a different requirement for IGF-IR signaling in
each cell line. Nevertheless, the synergism between the two
agents in vitro cannot be accounted for by a synergistic induc-
tion of cell cycle arrest.
Estrogen-dependent IGF-IR signaling via PI3K is altered 
by both letrozole and AEW541
Previous work has established bidirectional regulation of the
ER and IGF-IR pathways. For example, ER signaling can lead
to an upregulation of IGF-I family members [21,22], and IGF-
IR signaling activates ER-mediated gene transcription [36].
We therefore addressed, at the molecular level, the synergistic
mechanism of letrozole and AEW541 regarding proliferation
and apoptosis of MCF7/Aro cells. This required analysis of
two independent time points, namely an early 24-hour time
point (for proliferation events) and a late 96-hour time point (for
apoptosis events). Data are again presented from one experi-
ment but were reproducible over three independent experim
ents.
In order to monitor effects on proliferation, cells were stimu-
lated simultaneously with Δ4A and treated for 24 hours with
both agents alone or in combination (Figure 3a) before
processing for Western blotting. As expected, IGF-IRβ and
insulin receptor substrate (IRS)-1 protein levels as well as
phosphorylation of IRS-1 increased upon addition of Δ4A (Fig-
ure 3a; compare lanes 1 and 2). Letrozole and AEW541 both
reverted these effects, and combination of the two exhibited
additive inhibition (Figure 3a; compare lane 2 versus lanes 3
to 5). Protein and phospho-protein levels of two independent
downstream signaling kinases, namely protein kinase B
(PKB)/Akt and MAPK, were also assessed. Strikingly, phos-
pho-MAPK levels appeared to be unaffected by either com-
pound treatment, whereas phospho-PKB/Akt levels decreas
ed in the presence of either agent (Figure 3a; compare lane 2
versus lanes 3 and 4). Moreover, combination of the two com-
pounds was additive in lowering phospho-PKB/Akt levels as
well as upstream pathway members IGF-IRβ, IRS-1, and phos-
pho-IRS-1 (Figure 3a; compare lane 2 versus lanes 3, 4 and
5). ERα was not detectable (data not shown). Hence, combi-
nation of AEW541 and letrozole appears to inhibit PI3K (but
not MAPK) signaling to a greater extent than either agent
alone.
Morphologic analysis of cells over a period of 6 days revealed
that dead cells began to appear 4 days after compound treat-
ment. Therefore, cells were treated for 96 hours simultane-
ously with Δ4A and increasing concentrations of either agent
alone or in combination, before being processed for Western
blotting. Addition of Δ4A led to the upregulation of IGF-IRβ
and IRS-1 protein levels (Figure 3b; compare lanes 1 and 11),
Table 2
Summary of combination index values for AEW541 and 
letrozole
Cell line Fa Compound IC50 (nmol/l) DRI CI
MCF7/Aro 0.5 AEW541 33 5.9 0.888
Letrozole 158 1.6
0.75 AEW541 55 7.7 0.597
Letrozole 265 2.4
0.9 AEW541 92 10.0 0.406
Letrozole 445 3.6
T47D/Aro 0.5 AEW541 268 7.9 0.513
Letrozole 13 3.0
0.75 AEW541 3326 10.0a 0.284
Letrozole 166 4.4
Combination index (CI) values above 1.1 indicate antagonistic, 0.9 to 
1.1 additive, 0.7 to 0.9 moderately synergistic, 0.3 to 0.7 synergistic, 
and under <0.3 strongly synergistic. Note that the effective dose at 
50%, 75% and 90% inhibition is decreased when both agents are 
combined. aDRI is greater than 10 (outside of concentration range). 
DRI, dose response index; Fa, fraction affected; IC50, 50% inhibitory 
concentration.Breast Cancer Research    Vol 10 No 4    Lisztwan et al.
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as also seen at 24 hours (Figure 3a). Confirming previous
work [37], letrozole induced a modest upregulation of ERα
and IGF-IRβ in the presence of Δ4A after 96 hours, but dra-
matically decreased levels of IRS-1 (Figure 3b; compare lane
1 versus lanes 5 to 7). Interestingly, even after 4 days of com-
pound treatment, no effect on phospho-protein levels of MAPK
or a related family member, p38MAPK, were observed (Figure
3b and Additional file 2). However, phospho-PKB/Akt levels
remained inhibited by both AEW541 and letrozole in a
concentration-dependent manner (Figure 3b; compare lane 1
versus lanes 2 to 4 and 5 to 7). This inhibition was again addi-
tive when both agents were combined for 96 hours (Figure 3b;
compare lanes 4 and 7 versus lane 10). Interestingly, culturing
cells for 4 days in the absence of Δ4A led to an upregulation
of phospho-PKB and, to a lesser degree, phospho-IRS-1 (Fig-
ure 3b, lane 11), whereas phospho-MAPK and phospho-
p38MAPK levels remained unchanged, once again highlight-
ing the importance of PI3K/PKB/Akt signaling in mediating
survival when estrogen signals are absent.
Hence, our data indicate that MCF7/Aro cells lose estrogen
survival signals after addition of letrozole, which can most eas-
ily be monitored through changes in IRS-1, ER [37], and IGF-
IR [38] protein levels, even at suboptimal concentrations.
These survival signals appear to be mediated by PI3K/PKB/
Akt signaling, which is additively suppressed by addition of
both AEW541 and letrozole. Notably, although there were
similarities between the molecular events monitored at 24 and
96 hours, clear differences in phospho-PKB and phospho-
IRS-1 responses could be observed, emphasizing the need to
discriminate between early and late events when studying
molecular responses to drug treatment.
AEW541 and letrozole treatment shows combined 
proapoptotic potential
Further analysis of our Western blots with two apoptotic mark-
ers for MCF7 cells [39], namely caspase 9 and PARP (poly
[ADP-ribose] polymerase), revealed cleavage of these pro-
teins upon treatment with suboptimal concentrations of either
Table 3
Summary of altered cell cycle distribution in response to treatment with single agent or in combination
Cell line Compound Sub-G1 (%) G1 phase (%) S phase (%) G2/M phase (%) Annexin/7-AAD (%)
MCF7Aro (24 hours) -Δ4A 2.5 77.7 11.1 9.3 3.5
+Δ4A 1.6 39.9 41.8 17.5 2.8
AEW541 (92 nmol/l) 2.2 44.0 39.1 15.1 3.2
Letrozole (445 nmol/l) 3.1 74.2 12.8 10.7 2.7
AEW541 + Letrozole 2.4 78.4 10.1 9.5 2.3
T47D/Aro -Δ4A 0.6 86.5 4.1 8.1 ND
+Δ4A 0.6 77.9 10.1 10.7 ND
AEW541 (3.3 μmol/l) 0.3 83.8 6.2 9.0 ND
Letrozole (165 nmol/l) 0.4 84.2 6.5 8.3 ND
AEW541 + letrozole 0.4 87.3 3.8 8.1 ND
MCF7/Aro (96 hours) -Δ4A 6.2 64.8 4.9 24.4 23.7
+Δ4A 1.8 65.3 13.0 20.4 5.8
AEW541 (92 nmol/l) 2.6 59.0 14.8 23.9 5.5
Letrozole (445 nmol/l) 3.3 59.0 14.1 24.0 11.2
AEW541 + Letrozole 7.3 58.7 12.2 22.4 22.5
T47D/Aro (96 hours) -Δ4A 3.9 77.9 4.8 11.9 ND
+Δ4A 0.9 68.2 16.7 13.4 ND
AEW541 (3.3 μmol/l) 4.4 71.0 12.6 10.7 ND
Letrozole (165 nmol/l) 1.6 80.8 5.8 10.8 ND
AEW541 + letrozole 5.0 77.2 4.3 11.7 ND
Steroid-deprived MCF7/Aro and T47D/Aro cells were treated for 24, 48, or 96 hours with either no androstenedione (Δ4A; -Δ4A), Δ4A in the 
presence of dimethyl sulfoxide (+Δ4A), or Δ4A in the presence of the indicated concentrations of compound. Cells were processed for 
fluoresence-activated cell sorting (FACS) using propidium iodide and AnnexinV/7-AAD staining, as described in the text. Percentage distribution 
of cells in each cell cycle phase and total Annexin V stained cells are shown. The percentage value corresponds to upper and lower right 
quadrants of FACS plots in Figure 4b. ND, not determined.Available online http://breast-cancer-research.com/content/10/4/R56
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AEW541 or letrozole, indicating induction of apoptosis (Fig-
ure 3b; compare lane 1 versus lanes 2 to 10). In order to fur-
ther quantitate induction of apoptosis, we processed cells for
flow cytometry analysis in three independent experiments. At
96 hours, cells treated with AEW541 and/or letrozole showed
either no or less significant differences in their cell cycle pro-
files (Figure 4a and Table 3; compare percentages for G1, S
and G2/M phases at 96 hours in Table 3). In contrast, the sub-
G1 population appeared to increase when cells were treated
with a combination of both compounds, which is indicative of
an increasing pool of apoptotic cells. In order to confirm the
presence of apoptotic cells, MCF7/Aro cells were double-
stained with 7-AAD/Annexin V. Under these experimental con-
ditions, Annexin V staining in Δ4A-treated cells was nearly
absent as compared with cells that had been steroid deprived
(Figure 4b and Table 3; compare 5.8% versus 23.7% of the
cell population, respectively, in the ANX% column). As a single
agent, letrozole exhibited no significant increase in the apop-
totic population in either cell line. The same was observed for
AEW541 in MCF7/Aro cells, whereas T47D/Aro cells were
sensitive to IGF-IR inhibition and increased their sub-G1 pop-
ulation. More importantly, however, combining AEW541 with
letrozole enhanced the apoptosis-inducing effect of both
agents alone (for example, compare 11% versus 23% Annexin
V staining in MCF7/Aro cells), even to the level seen in cells
that were steroid-deprived (22.5% versus 23.73%), suggest-
ing that this combination mimics the effect of depriving the
cells of estrogens. Taken together, our data would suggest
that a combination of AEW541 and letrozole is synergistic
through increasing apoptotic responses in estrogen-depend-
ent cells.
Discussion
Crosstalk between the ER and IGF-IR pathways is critical for
normal breast development, but also for the initiation, mainte-
nance, and progression of breast cancer [25]. This would
argue that a combined inhibition of both pathways is neces-
sary to observe synergistic antiproliferative/proapoptotic
Figure 2
Letrozole, but not AEW541, shows antiproliferative activity at suboptimal concentrations Letrozole, but not AEW541, shows antiproliferative activity at suboptimal concentrations. Steroid-deprived MCF7/Aro and T47D/Aro cells were 
treated for 24 and 48 hours, respectively, with either no androstenedione (Δ4A; -Δ4A), Δ4A in the presence of dimethyl sulfoxide (DMSO; +Δ4A), or 
Δ4A in the presence of the indicated concentrations of compound. Cells were processed for fluorescence-activated cell sorting using propidium 
iodide (as described in the text). G1/S ratio was calculated by dividing G1 phase values by S phase values (see Table 3).Breast Cancer Research    Vol 10 No 4    Lisztwan et al.
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effects in breast cancer cells. Indeed, by combining a selective
IGF-IR inhibitor, AEW541 [18], with letrozole, we provide evi-
dence for synergistic inhibition of proliferation of two inde-
pendent aromatase over-expressing breast cancer cell lines,
namely MCF7/Aro and T47D/Aro. These in vitro studies dem-
onstrate the potential value of the combination. However, the
translation of these observations into the clinic requires further
studies, including assessment of the combination in appropri-
ate animal models. Nevertheless, to our knowledge, this is the
first study that clearly establishes the possibility that synergis-
tic responses can be obtained in the clinic by combining IGF-
IR inhibition with aromatase inhibition in the estrogen-depend-
ent cancer setting.
It is worth noting that a similar rationale was previously applied
in two different breast cancer xenograft models, in which com-
bination of the anti-estrogen tamoxifen with an IGF-IR antibody
proved to be more effective in suppressing tumor growth in
vivo as compared with the single agent alone [38,40]. Further
analysis of these tumor samples after 50 days of tamoxifen
treatment alone revealed increased levels of IGF-IR [38]. Sim-
ilar effects were observed with letrozole, for which increases
in erbB2 and ERα levels were observed 4 weeks after initiat-
ing treatment [41]. We also observed in our in vitro models
that letrozole decreases IGF-IR levels within 24 hours, fol-
lowed by a clear increase in IGF-IR and ERα levels 72 hours
later. The reason for this effect is not well understood. It is
known that addition of an IGF-IR antibody decreases the levels
of the receptor, most likely by mimicking IGF-I ligand in its abil-
ity to increase endocytosis and degradation of the receptor
[42]. It therefore may be that as cells adapt to the presence of
anti-endocrine therapy, the receptor is stabilized in the absen
ce of ligand and sensitized to any ligand which becomes later
available [43]. Interestingly, we observed an additive effect of
AEW541 and letrozole leading to increased IGF-IRβ levels.
Although this observation fits with previously published in vivo
observations, we feel that it also has important implications for
selecting a tyrosine kinase inhibitor for combination with aro-
matase inhibitors. More specifically, recent work indicates epi-
dermal growth factor receptor (EGFR) signaling in breast
cancer cells cannot compensate for loss of IGF-IR signaling
[44]. Hence, although EGFRmay also be upregulated in resp
onse to anti-endocrine agents, a molecule that inhibits IGF-IR
signaling would be predicted by these data to be more effec-
tive as an anticancer agent.
MCF7 cells over-expressing aromatase (MCF7/Aro) not only
mimic in vitro the estrogen dependency of breast cancer, but
they also have been shown to be a predictive preclinical model
for anti-endocrine therapies in the clinic [37]. Although we
could show that IGF-IR signaling is required for estrogen-
dependent proliferation of both MCF7/Aro and, to a lesser
extent, T47D/Aro cells, the fact that we did not observe a syn-
ergistic effect on cell cycle arrest when combining suboptimal
concentrations of AEW541 with letrozole suggests that estro-
gen signaling is upstream and/or independent of IGF-IR. Both
Figure 3
Letrozole and AEW541 both modulate IGF-IR pathway signaling via the PI3K/PKB axis Letrozole and AEW541 both modulate IGF-IR pathway signaling via the PI3K/PKB axis. (a) Steroid-deprived MCF7/Aro cells were treated for 24 
hours with either no androstenedione (Δ4A; lane 1), Δ4A in the presence of dimethyl sulfoxide (DMSO; lane 2), or Δ4A in the presence of 92 nmol/l 
AEW541 (lane 3) or 445 nmol/l letrozole (lane 4), or both combined (lane 5). Cells were processed for Western blotting with specific antibodies for 
the proteins indicated. Note that samples were processed in parallel to fluoresence-activated cell sorting (FACS) data shown in Figure 2. (b) Ster-
oid-deprived MCF7/Aro cells were treated for 96 hours with either no Δ4A (lane 11), Δ4A in the presence of DMSO (lane 1), or Δ4A in the presence 
of 33, 55, and 92 nmol/l AEW541 (lanes 2 to 4), 158, 265 and 445 nmol/l letrozole (lanes 5 to 7), or both respectively combined (lanes 8 to 10). 
Cells were processed for Western blotting with specific antibodies for the proteins indicated. Note that samples were processed in parallel to FACS 
data displayed in Figure 4. *Background band. Casp, caspase; IGF-IR, insulin-like growth factor I receptor; IRS, insulin receptor substrate; MAPK, 
mitogen-activated protein kinase; PARP, poly [ADP-ribose] polymerase; PKB, protein kinase B.Available online http://breast-cancer-research.com/content/10/4/R56
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E2 and IGF-I synergistically provide proliferation signals to
breast cancer cells, but E2 is essential for the proliferation of
MCF7 cells [45]. Indeed, IGF-I signaling is nonmitogenic in the
absence of ERα [45-47] and may even play a role in promoting
invasion in ER-negative breast cancers [47]. This, however,
does not mean that IGF-IR signaling is expendable in breast
carcinogenesis. Transgenic mice for the IGF-I pathway, over-
expressing IGF-I, IGF-IR, or IRS1 and IRS2 in the mammary
gland, all develop breast adenocarcinomas [12,13,48,49].
Hence, although our data would suggest that IGF-IR is not
always the primary proliferative signal in estrogen-dependent
breast cancer, it may provide critical pro-survival signals.
Several data support this hypothesis. First, we observed
AEW541 as a single agent induced apoptosis in T47D/Aro
cells and could greatly enhance the proapoptotic potential of
letrozole in MCF7/Aro cells. Second, combination of AEW541
and letrozole was not synergistic for inducing cell cycle arrest
in cells, but did appear to be synergistic in MCF7/Aro cells via
the decrease in levels of phospho-PKB/Akt, which is a classi-
cal target of PI3K signaling and mediator of prosurvival events.
Finally, we observed that letrozole consistently sensitized cells
to addition of AEW541, as reflected in higher dose response
index values for AEW541. This suggests that aromatase plays
a central role in mediating estradiol-dependent proliferation/
survival, not only through ER but also through IGF-IR. Hence,
Figure 4
Letrozole and AEW541 exhibit synergistic proapoptotic activity at suboptimal concentrations Letrozole and AEW541 exhibit synergistic proapoptotic activity at suboptimal concentrations. (a) Steroid-deprived MCF7/Aro and T47D/Aro cells 
were treated for 96 hours with either no Δ4A (-Δ4A), Δ4A in the presence of dimethyl sulfoxide (DMSO; +Δ4A), or Δ4A in the presence of the indi-
cated concentrations of compound. Cells were processed for fluoresence-activated cell sorting (FACS) using propidium iodide as described. Per-
centage of cells in sub-G1 is indicated. (b) Steroid-deprived MCF7/Aro cells were treated for 96 hours with either no Δ4A (-Δ4A), Δ4A in the 
presence of DMSO (+Δ4A), or Δ4A in the presence of the indicated concentrations of compound. Cells were processed for FACS using 7-AAD/
Annexin V staining and apoptotic subpopulations identified as described in the Materials and methods section. Note that the apoptotic population 
resides in the upper and lower right panels of the 7-AAD/Annexin V stained cells (circled by the dotted line). PI, propidium iodide.Breast Cancer Research    Vol 10 No 4    Lisztwan et al.
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although IGF-IR can in its own right transform cells and act syn
ergistically with estrogen-signaling, it appears that the ability to
promote survival of breast cancer cells may also be a critical
function.
One of the advantages of a combination therapy is to prevent
or delay the onset of resistance. Much work has been con-
ducted on the topic of development of resistance to tamoxifen,
which has an average time to progression of 6 months
[50,51]. Despite the benefits of anti-endocrine therapy to
breast cancer patients, a subset of breast cancers eventually
develop resistance, thereby circumventing long-term depriva-
tion of estrogen [52]. The mechanisms underlying this process
have been modeled by several groups in vitro, in which upreg-
ulation of growth factor receptor pathways (namely Her2 or
EGFR) in ER-positive cells led to a loss of ER dependency
[53,54]. Notably, IGF-IR has also been linked in vitro to devel-
opment of resistance to tamoxifen [55] and trastuzumab [56].
In vivo work with letrozole has revealed that erbB2 is highly
induced at 4 weeks of treatment, before development of resist-
ance [41]. Notably, no study to date has linked IGF-I signaling
to development of resistance in vivo, beyond the observation
that IGF-IR levels increase in the presence of an anti-endo-
crine agent (our observations and those of Ye and coworkers
[38]). However, several observations suggest that IGF-IR may
be required for maintaining the transformed state: IGF-IR is
required for the transformation of fibroblasts by SV40 [57], it
is able to improve the efficiency of EGFR signaling in
tamoxifen-resistant cells [52], and its inhibition enhances the
inhibitory effects of gefitinib in breast cancer cells [58].
Although letrozole has proven to be superior to tamoxifen in
the treatment of endocrine-dependent breast cancers [3-
6,50,51], resistance may also eventually develop [59,60].
Therefore, combined therapies of letrozole and IGF-IR inhibi-
tion may provide multiple benefits. First, inhibition of IGF-I sig-
naling could improve the efficacy of letrozole, and is highly
supported by our synergistic in vitro results and by other pub-
lished in vivo studies [38,40]. Second, inhibition of both path-
ways could not only suppress growth of estrogen-dependent
breast cancers but may also prevent development of a popu-
lation of resistant cells with upregulated, IGF-IR-dependent
survival pathways and invasion [19,61]. A striking example of
this is a recent study revealing that inhibition of PI3K pathway
signaling improves response of letrozole-insensitive xeno
grafts [62]. It is therefore tempting to speculate on whether a
delay in the onset of insensitivity would be observed if letrozole
and an IGF-IR inhibitor were combined, leading to enhanced
inhibition of PI3K signaling (as shown in our study). Consider-
ing that the current response time to letrozole in advanced
metastatic breast cancer patients is 9.4 months (versus 6
months with tamoxifen) [50,51], a combination of an IGF-IR
inhibitor with an aromatase inhibitor may prolong response
time significantly. Third, it may also be possible to restore
estrogen-sensitivity to a previously endocrine-insensitive tum
or with an IGF-IR inhibitor. A precedent for this already exists
in work conducted in letrozole-resistant xenograft models
treated with gefitinib, an EGFR inhibitor [41]. Resistance is an
unfortunate reality in the clinic, and a recently reported clinical
study revealed that even with the combination of tamoxifen
with trastuzamab, an antibody targeting EGFR, there remains
a subset of patients who do not respond [63]. Hence, there is
still the need for preclinical and clinical combination studies to
elucidate the mechanisms of resistance developing upon anti-
endocrine treatments [60].
Conclusion
Our study emphasizes the importance of the IGF-IR pathway
in the estrogen-induced proliferative response, which is in full
agreement with previous studies. However, we report in this
study that IGF-IR signaling plays a critical role in providing pro-
survival signals in estrogen-driven proliferation of breast can-
cer cells. The fact that AEW541 and letrozole combine
synergistically to inhibit proliferation of cells and induce apop-
tosis suggests that this combination therapy may improve anti-
tumor efficacy in breast cancer patients. Furthermore, we pro-
vide evidence suggesting that the downregulation of the IGF-
IR/PI3K/PKB/Akt pathway could be applied as predictors of
efficacy in such a combination trial. We propose, therefore,
that combination of letrozole and an inhibitor of IGF-IR should
be explored further as a rational treatment for estrogen-
dependent breast cancer.
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